Topics
July/August 2018 | Subfocus: Drug Delivery
Topical Drug Delivery for Retinal Disease Management
The cornea and sclera stand in the way of this more convenient, less invasive drug delivery modality.
David S. Boyer, MD
November 10, 2026
Imvionix Acquires US and Canadian Commercial Rights to Beovu from Novartis
City Therapeutics Doses First Participant in Phase 1 Trial of CITY-RBP4 for Stargardt Disease
November 9, 2026
Viridian Therapeutics Reports Positive Phase 1 Results for VRDN-008, Plans Registrational Trial in 2027
Ianalumab Reduces Disease Activity in Sjögren’s Disease in Two Phase 3 Trials
October 2026 Insert
Editorially Independent Content, Supported With Advertising From Asetllas
Editorially independent supported by Abbvie and Regenxbio
Free Print Subscription
Email Newsletter
Conference Calendar
